Preventative health, longevity care, and biotech are crossing into mainstream wellness.
Noom launches labs
The behavior-change platform launched at-home biomarker kits designed to help users track how lifestyle changes and GLP-1 programs impact their health over time.
- Using painless microneedle collection devices, the tests measure 17 biomarkers tied to cholesterol, blood sugar, inflammation, hormones, and nutrition — with results delivered directly inside the Noom app.
- While many users appeared healthy, early program data found 70% had high LDL cholesterol levels and more than a third showed signs of prediabetes.
As consumers gain access to more health data, companies like Noom are trying to connect diagnostics, coaching, medication, and behavior change into one continuous feedback loop.
Scientists near a one-time treatment for high cholesterol
In a small early-stage study, a single gene-editing infusion lowered LDL cholesterol levels by as much as 62%, with some patients maintaining results for more than 18 months.
- The treatment works by permanently switching off a gene tied to cholesterol regulation, allowing the liver to continuously clear more LDL from the bloodstream.
- Researchers hope the therapy could eventually replace years—or even decades—of daily cholesterol medication for some patients.
While much larger studies are still needed, the results point toward a future where gene editing could shift from rare diseases into common chronic conditions like heart disease.
Retro Biosciences reaches a reported $1.8B valuation
Pushing deeper into longevity, the Sam Altman-backed company is developing treatments aimed at slowing or reversing age-related disease, including Alzheimer’s and cellular decline.
Its lead program recently entered human trials, testing whether boosting the body’s natural cellular cleanup process can help combat neurodegeneration.
As the longevity sector becomes more clinical, anti-aging science is evolving into mainstream biotech focused on extending healthspan and preventing chronic disease before it starts.
